Back to Search Start Over

Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study.

Authors :
Ju-Fang Shi
Jun-Feng Chen
Canfell, Karen
Xiang-Xian Feng
Jun-Fei Ma
Yong-Zhen Zhang
Fang-Hui Zhao
Rong Li1
Li Ma
Zhi-Fang Li
Jie-Bin Lew
Yan Ning
You-Lin Qiao
Source :
BMC Health Services Research; 2012, Vol. 12 Issue 1, p123-136, 14p, 1 Diagram, 5 Charts, 3 Graphs
Publication Year :
2012

Abstract

Background: Cost estimation is a central feature of health economic analyses. The aim of this study was to use a micro-costing approach and a societal perspective to estimate aggregated costs associated with cervical cancer screening, diagnosis and treatment in rural China. Methods: We assumed that future screening programs will be organized at a county level (population ~250,000), and related treatments will be performed at county or prefecture hospitals; therefore, this study was conducted in a county and a prefecture hospital in Shanxi during 2008-9. Direct medical costs were estimated by gathering information on quantities and prices of drugs, supplies, equipment and labour. Direct non-medical costs were estimated via structured patient interviews and expert opinion. Results: Under the base case assumption of a high-volume screening initiative (11,475 women screened annually per county), the aggregated direct medical costs of visual inspection, self-sampled careHPV (Qiagen USA) screening, clinician-sampled careHPV, colposcopy and biopsy were estimated as US$2.64,$7.49,$7.95,$3.90 and $5.76, respectively. Screening costs were robust to screening volume (<5% variation if 2,000 women screened annually), but costs of colposcopy/biopsy tripled at the lower volume. Direct medical costs of Loop Excision, Cold-Knife Conization and Simple and Radical Hysterectomy varied from $61-544, depending on the procedure and whether conducted at county or prefecture level. Direct non-medical expenditure varied from $0.68-$3.09 for screening/ diagnosis and $83-$494 for pre-cancer/cancer treatment. Conclusions: Diagnostic costs were comparable to screening costs for high-volume screening but were greatly increased in lower-volume situations, which is a key consideration for the scale-up phase of new programs. The study's findings will facilitate cost-effectiveness evaluation and budget planning for cervical cancer prevention initiatives in China. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14726963
Volume :
12
Issue :
1
Database :
Complementary Index
Journal :
BMC Health Services Research
Publication Type :
Academic Journal
Accession number :
82336190
Full Text :
https://doi.org/10.1186/1472-6963-12-123